RSS-Feed abonnieren
DOI: 10.1055/s-0038-1648985
Effect of Oestrogen Dose on Whole Blood Platelet Activation in Women Taking New Low Dose Oral Contraceptives
Publikationsverlauf
Received 28. März 1994
Accepted after resubmission 08. August 1994
Publikationsdatum:
26. Juli 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199406/lookinside/thumbnails/10-1055-s-0038-1648985-1.jpg)
Summary
Oral contraceptive use is known to cause changes in the haemostatic system. These changes are thought to be related to oestrogen dose and to provide a possible link between the increased risk of thromboembolic disease known to occur in women taking oestrogen containing oral contraceptives. This study measured whole blood platelet activation, serially, in women taking oral contraceptives containing 20 μg and 30 μg ethinyloestradiol combined with desogestrel. Increased levels of ADP and arachidonic acid induced aggregation were observed in women taking the 30 μg ethinyloestradiol combination. Platelet release of β-thromboglobulin (βTG) was also significantly increased. Increased collagen induced aggregation was observed but this failed to reach statistical significance for the individual treatment groups. In women taking the 20 μg ethinyloestradiol combination, a significant increase was only observed when platelets were stimulated with arachidonic acid. Platelet factor 4 (PF4) levels were unchanged in both groups. Significantly higher levels of βTG were observed in women taking the 30 μg ethinyloestradiol combination compared with women taking the 20 μg ethinyloestradiol combination. These results show that oral contraceptive use is associated with platelet activation. Women taking the 20 μg ethinyloestradiol combination show less changes in platelet activation than women taking the 30 μg ethinyloestradiol combination. This lower dose pill may therefore be particularly suitable for high risk women wishing to use oral contraception.
-
References
- 1 Vessey MP, Villard-Mackintosh L, McPherson K, Yeates D. Mortality among oral contraceptive users: 20 year follow-up study of women in a cohort study. Br Med J 1989; 299: 1487-1491
- 2 Thorogood M, Vessey M. An epidemiological survey of cardiovascular disease in women taking oral contraceptives. Am J Obstet Gynecol 1990; 163: 274-291
- 3 Hirvonen E, Idanpaan-Heikkila J. Cardiovascular death among women under 40 years of age using low dose oestrogen oral contraceptives and intra-uterine devices in Finland from 1975-1984. Am J Obstet Gynecol 1990; 163: 281-284
- 4 Lidegaard O. Oral contraception and risk of a cerebral thromboembolic attack: results of a case-control study. Br Med J 1993; 306: 956-963
- 5 Meade TW, Greenberg G, Thomson SG. Progestogens and cardiovascular reactions associated with oral contraceptives and a comparison of the safety of 50 ug and 30 ug oestrogen preparations. Br Med J 1980; 280: 1157-1161
- 6 Royal College of General Practitioners Oral Contraceptive Study. Recommendations from the findings of the RCGP oral contraceptive study on the mortality risks of oral contraceptive users. Br Med J 1977; 2: 947-948
- 7 Thomson JM, Poller L. Oral contraceptive hormones and blood coagulation. BrMed J 1965; 2: 270-273
- 8 Poller L, Tabiowo A, Thomson JM. Platelet aggregation during oral contraception. Br Med J 1968; 3: 218-219
- 9 Sabra A, Bonnar J. Haemostatic changes induced by 50 ug and 30 ug oestrogen/progestogen oral contraceptives. J Rep Med 1983; 28 (01) 85-91
- 10 Kunz F, Pechlaner C, Tabarelli M, Solder E, Zwierzina WD. Influence of oral contraceptives on coagulation tests in native blood and plasma. Am J Obstet Gynecol 1990; 163: 417-420
- 11 McGrath KM, Castaldi PA. Changes in coagulation factors and platelet function in response to progestational agents. Haemostasis 1975; 4: 65-72
- 12 Sadurska B, Taccioni MT, di Minno G, Roncaglioni MC, Pangrazzi J, Donati MB, Bizzi A, Silver MJ. Plasma and platelet lipid composition and platelet aggregation by arachidonic acid in women on the pill. Thromb Haemost 1981; 45: 150-153
- 13 Daly L, Bonnar J. Comparative studies of 30 ug ethinyloestradiol combined with gestogene and desogestrel on blood coagulation, fibrinolysis and platelets. Am J Obstet Gynecol 1990; 163: 430-437
- 14 Shevde N, Sussman II, Rossner F, Pacholuk V. Oral contraceptives and platelet aggregation. Am J Obstet Gynecol 1978; 132: 303-306
- 15 Poller L, Priest CM, Thomson JM, Thomas W, Wray C. Blood clotting and platelet aggregation during oral progestogen contraception: a follow-up study. Br Med J 1971; 1: 705-707
- 16 Farag AM, Bottoms SF, Mammen EF, Hosni MA, Ali AA, Moghissi KS. Oral contraceptives and the haemostatic system. Obstet Gynecol 1988; 71: 584-588
- 17 Fox SC, Burgess-Wilson M, Heptinstall S, Mitchell JRA. Platelet aggregation in whole blood determined using the Ultra-Flo-100 platelet counter. Thromb Haemost 1982; 48 (03) 327-329
- 18 Reiss H, Braun G, Brehm G, Hiller G. Critical evaluation of platelet aggregation in whole human blood. Am J Clin Path 1986; 85: 50-56
- 19 Lad N, Lunt DO, Tuffin DP. The effect of thromboxane A2 synthetase inhibitors on platelet aggregation in whole blood. Thromb Res 1987; 46: 555-566
- 20 Falcon C, Amout J, Vermylen J. Platelet aggregation in whole blood: studies with a particle counting technique-methodological applications and some applications. Thromb Haemost 1989; 61: 423-428
- 21 Norris LA, Bonnar J. The in vitro effect of aspirin on increased whole blood platelet aggregation in oral contraceptive users. Thromb Res 1994; 74 (03) 309-315
- 22 Norris LA, Bonnar J. Effect of oestrogen dose on haemostatic changes in oral contraceptive users. Ir J Med Sci 1993; 162 (Suppl. 02) 33
- 23 Ludlam CA, Moore S, Bolton AE, Pepper DS, Cash JD. Release of a human platelet specific protein measured by radioimmunoassay\. Thromb Res 1975; 6: 543-548
- 24 Kaplan KL, Owen J. Radioimmunoassay of platelet factor 4. Methods in Enzymology 1982; 84 (06) 83-93
- 25 Notelovitz M, Kitchens CS, Khan FY. Changes in coagulation and anticoagulation in women taking low dose triphasic oral contraceptives: A controlled comparative 12-month clinical trial. Am J Obstet Gynecol 1992; 167: 1255-1261
- 26 Cohen H, Mackie IJ, Walshe K, Gillmer MDG, Machin SJ. A comparison of the effects of two triphasic oral contraceptives on haemostasis. Br J Haematol 1988; 69: 259-263
- 27 Meade TW. Oral contraceptives, clotting factors and thrombosis. Am J Obstet Gynecol 1982; 142: 758-761
- 28 Gevers LeuvenJA, Kluft C, Bertina RM, Hessel LW. Effects of two low-dose oral contraceptives on circulating components of the coagulation and fibrinolytic systems. J Lab Clin Med 1987; 109: 631-636
- 29 Inauen W, Baumgartner HR, Haeberli H, Straub PW. Excessive deposition of fibrin, platelets and platelet thrombi on vascular subendothelium during contraceptive drug treatment. Thromb Haemost 1987; 57 (03) 306-309
- 30 Bolton CH, Hampton JR, Mitchell JRA. Effect of oral contraceptive agents on platelets and plasma phospholipids. Lancet 1968; i: 1336-1340
- 31 Eckles RS, Hampton JR, Mitchell JRA. Effect of oestrogen on human platelet behavioure. Lancete 1968; ii: 315-318
- 32 Poller L, Priest CM, Thomson JM. Platelet aggregation during oral contraceptione. Br Med J 1969; 4: 273-274
- 33 Davies T, Fieldhouse G, McNicol GP. The effects of therapy with oestriol succinate and ethinyl oestradiol on the haemostatic mechanism in post menopausal women. Thromb Haemost 1976; 35: 403-414
- 34 Nordoy A, Svensson B, Haycraft D, Hoak JC, Wiebe D. The influence of age, sex and the use of oral contraceptives on the inhibitory effects of endothelial cells and prostacyclin on platelet function. Scan J Haematol 1978; 21: 177-187
- 35 Ylikorkala O, Kuusi T, Tikkanen MJ, Viinika L. Desogestrel and levonor-gestrel containing oral contraceptives have different effects on urinary excretion of prostacyclin metabolites and serum high density lipoproteins. J Clin Endocrinol Metab 1987; 65: 1238-1242
- 36 Schorer AE, Gerrard JM, White JG, Krivit W. Oral contraceptive use alters the balance of platelet prostaglandins and thromboxane A2 synthesis. Prostaglandins and Medicine 1978; 1: 5-11
- 37 Elam MB, Lipscomb GE, Chesney CM, Terragno TA. Effect of synthetic oestrogen on platelet aggregation and vascular release of prostacyclin-like material in the rabbit. Prostaglandins 1980; 20: 1039-1051
- 38 Ylikorkala O, Poulakka J, Viinikka L. The effect of oral contraceptives on anti-aggregatory prostacyclin and thromboxane A4 in humans. Am J Obstet Gynecol 1982; 142: 573-576
- 39 Sinzinger H, Klein K, Kaliman J, Silberbauer K, Feigl W. Enhanced prostacyclin formation in veins of women under chronic treatment with oral contraceptive drugs. Pharmacol Res Commun 1980; 12: 515-521
- 40 Pan J-QI, Hall ER, Wu KK. Alteration of platelet responses to metabolites of arachidonic acid by oral contraceptives. Br J Haem 1984; 58: 317-323
- 41 Aranda M, Saez M, Abril V, Carrach J, Castells E, Castellanos JM. β-thromboglobulin and oral contraception. Lancet 1979; ii: 308-309
- 42 Huch KM, Elam MB, Chesney CM. Oral contraceptive steroid induced platelet coagulant hyperactivity: dissociation of in vivo and in vitro events. Thromb Res 1987; 48: 41-50
- 43 Needleman SW, Stump DC, Cohen DP. Catecholoestrogens and thrombosis lack of direct effect of 2-hydroxy-estradiol on platelets. Contraception 1982; 25: 185-189
- 44 Poller L, Thomson JM, Thomas PW. Effects of progestogen oral contraception with norethisterone on blood clotting and platelets. Br Med J 1972; 4: 391-393
- 45 Melis GB, Frussetti F, Nicoletti N, Ricci C, Lammers P, Atsma WJ, Fioretti P. A comparative study of the effects of a monophasic pill containing desogestrel plus 20 ug ethinyloestradiol, a triphasic combination containing gestodene on coagulatory factors. Contraception 1991; 43 (01) 23-31
- 46 Stadel BV. Oral contraceptives and cardiovascular diseasee. N Engl J Med 1981; 305: 672-677